Cancer Therapeutic Procedure
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
ImmunityBio Trims Workforce Despite Recent FDA Approval for Anktiva
ImmunityBio, Anktiva, FDA approval, layoffs, financial challenges, bladder cancer treatment
ImmunityBio Secures FDA Approval for ANKTIVA but Faces Financial Challenges
ImmunityBio, FDA approval, ANKTIVA, financial troubles, cancer treatment, IL-15 agonist immunotherapy
Novartis Expands Radioligand Therapy Production with Two New US Facilities
Novartis, radioligand therapy, RLT, cancer treatment, manufacturing facilities, US expansion
Bicara and Zenas File for IPOs to Advance Late-Phase Cancer and Autoimmune Treatments
Bicara Therapeutics, Zenas BioPharma, IPO, cancer treatment, autoimmune disease, biotech, pharmaceuticals
FDA Delays Approval of Regeneron’s Multiple Myeloma Drug Due to Manufacturing Issues
Regeneron, linvoseltamab, multiple myeloma, FDA rejection, manufacturing issues, bispecific antibody, cancer treatment
Adcendo Secures $1 Billion Deal for Multitude’s Anti-TF ADC
Adcendo, Multitude Therapeutics, anti-TF ADC, $1 billion deal, biobucks, antibody-drug conjugate, cancer treatment
FDA Clears BioNTech-MediLink ADC Trial to Resume with Reduced Doses
BioNTech, MediLink, ADC trial, FDA approval, lower doses, cancer treatment, HER3, patient safety
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.